Identity
- Security key
- 12623
- Ticker
- BLCO
- Type
- CS — Common Stock
- Exchange
- New York Stock Exchange(XNYS)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2022-05-06
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- BLCO
Detail
Enriched 2026-08-14 20:47
- Market cap
- $5,986,089,522.96
- Shares outstanding (class)
- 357,166,599
- Shares outstanding (weighted)
- 357,165,246
- SIC
- 3851 OPHTHALMIC GOODS
- Employees
- 13,000
- Location
- VAUGHAN, A6
- Homepage
- https://www.bausch.com
- Description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.